Founder, CEO
AUM Biosciences
AUM Biosciences is developing precision oncology therapeutics that utilize multi-faceted inhibition strategies to combat cancer resistance mechanisms. The company targets the challenge of evolving cancer cells that evade treatment, aiming to enhance the effectiveness of existing therapies in the Asian market.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$29.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Cancer cells often develop resistance to anti-cancer therapies by mutating and evading the immune system. This resistance limits the effectiveness of existing treatments, especially in populations where certain genetic profiles are more prevalent.
Solution
AUM Biosciences is developing precision oncology therapeutics designed to overcome cancer resistance through multi-faceted inhibition strategies. Their approach targets the mechanisms that allow cancer cells to evade treatment, aiming to improve the efficacy of existing therapies. By addressing the root causes of resistance, AUM Biosciences seeks to provide more effective and durable treatment options for cancer patients.
Target Audience
The primary target audience includes cancer patients who have developed resistance to existing therapies, as well as oncologists seeking more effective treatment options for their patients.
Features
- Focus on multi-faceted inhibition strategies to combat resistance mechanisms.
- Development of precision oncology therapeutics.
- Clinical pipeline targeting specific cancer resistance pathways.